Special Edition

Special Edition

Nilotinib Improves Prognosis in Elderly Patients with Ph+ ALL

For the difficult-to-treat elderly population (aged ≥55 years) with Philadelphia chromosome positive (Ph+) acute lymphocytic leukemia (ALL), combining age-adapted, low-intensity chemotherapy with nilotinib is...
Advertisement

Current Issue

September 2019 Volume 5 Issue 11

September 2019, Volume 5, Issue 11

This issue explores politics in the exam room, demystifies proteomic analysis in hematology, and more.